OBJECTIVE: Preliminary evidence suggests that omega-3 fatty acids may reduce hyperactivity in children with autism spectrum disorder (ASD). We sought to examine the feasibility of a novel, Internet-based clinical trial design to evaluate the efficacy of this supplement. METHOD: E-mail invitations were sent to parents of children aged 5 to 8 years enrolled in the Interactive Autism Network. All study procedures, including screening, informed consent, and collection of outcome measures took place over the Internet. The primary outcome measures were parent- and teacher-rated changes in hyperactivity on the Aberrant Behavior Checklist (ABC-H). RESULTS: During the 6-week recruitment period, 57 children from 28 states satisfied all eligibility criteria and were randomly assigned to 1.3 grams of omega-3 fatty acids or an identical placebo daily for 6 weeks. Outcome assessments were obtained from all 57 participants and 57 teachers, and the study was completed in 3 months. Children in the omega-3 fatty acid group had a greater reduction in hyperactivity (-5.3 points) compared to the placebo group (-2.6 points), but the difference was not statistically significant (1.9-point greater improvement in the omega-3 group, 95% CI = -2.2 to 5.2). Adverse events were rare and not associated with omega-3 fatty acids. Participant feedback was positive. CONCLUSION: Internet-based, randomized controlled trials of therapies in children with ASD are feasible and may lead to marked reductions in the time and cost of completing trials. A larger sample size is required to definitively determine the efficacy of omega-3 fatty acids. Clinical trial registration information-Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder; http://clinicaltrials.gov; NCT01694667.
RCT Entities:
OBJECTIVE: Preliminary evidence suggests that omega-3 fatty acids may reduce hyperactivity in children with autism spectrum disorder (ASD). We sought to examine the feasibility of a novel, Internet-based clinical trial design to evaluate the efficacy of this supplement. METHOD: E-mail invitations were sent to parents of children aged 5 to 8 years enrolled in the Interactive Autism Network. All study procedures, including screening, informed consent, and collection of outcome measures took place over the Internet. The primary outcome measures were parent- and teacher-rated changes in hyperactivity on the Aberrant Behavior Checklist (ABC-H). RESULTS: During the 6-week recruitment period, 57 children from 28 states satisfied all eligibility criteria and were randomly assigned to 1.3 grams of omega-3 fatty acids or an identical placebo daily for 6 weeks. Outcome assessments were obtained from all 57 participants and 57 teachers, and the study was completed in 3 months. Children in the omega-3 fatty acid group had a greater reduction in hyperactivity (-5.3 points) compared to the placebo group (-2.6 points), but the difference was not statistically significant (1.9-point greater improvement in the omega-3 group, 95% CI = -2.2 to 5.2). Adverse events were rare and not associated with omega-3 fatty acids. Participant feedback was positive. CONCLUSION: Internet-based, randomized controlled trials of therapies in children with ASD are feasible and may lead to marked reductions in the time and cost of completing trials. A larger sample size is required to definitively determine the efficacy of omega-3 fatty acids. Clinical trial registration information-Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder; http://clinicaltrials.gov; NCT01694667.
Authors: Stephen J Blumberg; Matthew D Bramlett; Michael D Kogan; Laura A Schieve; Jessica R Jones; Michael C Lu Journal: Natl Health Stat Report Date: 2013-03-20
Authors: Marlene P Freeman; Joseph R Hibbeln; Katherine L Wisner; John M Davis; David Mischoulon; Malcolm Peet; Paul E Keck; Lauren B Marangell; Alexandra J Richardson; James Lake; Andrew L Stoll Journal: J Clin Psychiatry Date: 2006-12 Impact factor: 4.384
Authors: L Eugene Arnold; Michael G Aman; Amelia M Cook; Andrea N Witwer; Kristy L Hall; Susan Thompson; Yaser Ramadan Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-10 Impact factor: 8.829
Authors: G Paul Amminger; Miriam R Schäfer; Konstantinos Papageorgiou; Claudia M Klier; Sue M Cotton; Susan M Harrigan; Andrew Mackinnon; Patrick D McGorry; Gregor E Berger Journal: Arch Gen Psychiatry Date: 2010-02
Authors: Randall Owen; Linmarie Sikich; Ronald N Marcus; Patricia Corey-Lisle; George Manos; Robert D McQuade; William H Carson; Robert L Findling Journal: Pediatrics Date: 2009-12 Impact factor: 7.124
Authors: Ronald N Marcus; Randall Owen; Lisa Kamen; George Manos; Robert D McQuade; William H Carson; Michael G Aman Journal: J Am Acad Child Adolesc Psychiatry Date: 2009-11 Impact factor: 8.829
Authors: Sarah A Keim; Barbara Gracious; Kelly M Boone; Mark A Klebanoff; Lynette K Rogers; Joseph Rausch; Daniel L Coury; Kelly W Sheppard; Jesse Husk; Dale A Rhoda Journal: J Nutr Date: 2018-02-01 Impact factor: 4.798
Authors: Kelly M Boone; Mark A Klebanoff; Lynette K Rogers; Joseph Rausch; Daniel L Coury; Sarah A Keim Journal: Early Hum Dev Date: 2022-05-19 Impact factor: 2.699
Authors: Sarah A Keim; Abigail Jude; Katie Smith; Aiman Q Khan; Daniel L Coury; Joseph Rausch; Shivika Udaipuria; Megan Norris; Lindsay R Bartram; Anita R Narayanan; Lynette K Rogers Journal: J Autism Dev Disord Date: 2022-01-11
Authors: Kelly W Sheppard; Kelly M Boone; Barbara Gracious; Mark A Klebanoff; Lynette K Rogers; Joseph Rausch; Christopher Bartlett; Daniel L Coury; Sarah A Keim Journal: J Autism Dev Disord Date: 2017-11